Goldman Calls Medicis (MRX) 'One of the Most Likely M&A Targets' in Specialty Pharma Space

May 25, 2012 11:38 AM EDT Send to a Friend
Get Alerts MRX Hot Sheet
Price: $43.98 --0%

Rating Summary:
    6 Buy, 13 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 27 | Down: 26 | New: 17
Trade MRX Now!
Join SI Premium – FREE
Shares of Medicis Pharma (NYSE: MRX) are outperforming the broader equity market Friday morning following some promising comments from a Goldman Sachs' analyst earlier. While the stock is up about 1.8 percent at last check, the Dow and S&P 500 are down 17 points and up 1.8, respectively.

The firm said, "we believe the growth outlook remains underappreciated, with upside driven by Rx Assist initiatives (driving ASP improvement), new physician targeting strategies, and the launch of Zyclara. Further, we see MRX as one of the most likely M&A targets in the space, which should provide support amidst current market uncertainty."

Goldman maintains a Buy rating and $45 price target on shares of Medicis.

With the stock last trading around $37.10, the firm's price target implies potential upside of about 21 percent.

Track all the market-moving analyst calls on shares of Medicis with our Analyst Ratings page.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Goldman Sachs, Standard & Poor's

Add Your Comment